Answers are grounded in this paper and cite their sources.
Background Target Product Profiles (TPPs) serve as tools for planning medical innovation development, facilitating communication with regulators, and developing market access strategies. Modelling can assist TPPs development and provide guidance on defining attributes. This scoping review aims to define the general steps in employing models in developing or refining TPPs and to identify the common themes of the attributes informed by modelling. Methods PRISMA-ScR checklist was used to guide this review. Literature search in PubMed, Scopus, Web of Science, Embase, and the WHO Institutional Repository for Information Sharing (IRIS) was conducted between August and September 2023. Subsequently, two researchers reviewed abstracts independently. Only full text articles used modelling to inform TPPs of health technologies with detailed modelling and methodology reported were included in this review. General information, technology-related information, TPP-related information, and model-related information were extracted from the articles and analysed thematically. EPIFORGE 2020 checklist was used to assess the reporting quality of modelling approach of the included articles. Results This review included 23 articles published from 2010 onward, reflecting a growing interest in using modelling to inform TPP development. The studies covered diverse medical innovations such as drugs, vaccines, devices, procedures, and vector control tools. Commonly modelled attributes for device included health impact, economic value, and efficacy. For non-device innovations, clinical efficacy, economic value, and dosage were most frequently examined. The modelling process typically involved three steps: scoping, model development and validation, and analysis with recommendations. Limitations from the modelling process discussed across studies fell into three categories: evidence quality, modelling assumptions and structure, and the generalisability of findings. While some attributes, like clinical efficacy, are straightforward to model, certain attributes such as human factors require considering proxies like compliance rates or capacity constraints. Conclusions This review identified the common types of product attributes described in TPPs development that were informed by modelling, the modelling process, and their limitations. We provided recommendations for improving the modelling approach in TPPs development and highlighted the need for further research to standardise the modelling process. Public Interest Summary Target Product Profiles (TPPs) are documents that help outline targets for new medical innovations that are crucial to effectively address specific public healthcare needs. These documents are developed through multiple rounds of consultations with domain experts and stakeholders. We aimed to study how mathematical modelling can be used to assist TPP development. Through a systematic search, we identified and studied 23 papers that used modelling. We identified a structured three-step process: identifying the suitable model, testing and tuning the model, and using the model outputs to set the targets. TPP developers primarily used modelling to establish targets relating to the effectiveness and cost of the medical invention. Our findings contribute to a better understanding of modelling in TPP development and inform potential future guidance.
No takes yet. Share an insight, caveat, or question.
Phasitthanaphak et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: